
Pancreatic cancer with <em>BRCA1</em>and <em>BRCA2 </em>mutations has shown positive responses to the PARP inhibitor olaparib in preliminary trials.

Your AI-Trained Oncology Knowledge Connection!


Pancreatic cancer with <em>BRCA1</em>and <em>BRCA2 </em>mutations has shown positive responses to the PARP inhibitor olaparib in preliminary trials.

Published: July 15th 2019 | Updated: